Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionBispecific hexavalent antibody generated via the dock and lock (DNL) method that consists of 4 antigen-binding regions of veltuzumab, a humanized anti-CD20 antibody, conjugated to milatuzumab, a humanized anti-CD74 antibody
Molecular Target CD20 ; CD74 molecule major histocompatibility complex class II invariant chain
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationMantle cell lymphoma (MCL)
Indication DetailsTreat mantle cell lymphoma (MCL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today